Charles River Enhances Cell Therapy Flex Platform through Collaboration with Akadeum Life Sciences
(NYSE:CRL) WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Integration of Akadeum’s GMP-grade Human T Cell Leukopak Isolation Kit into Charles River’s Cell Therapy Flex Program announced today
Related Questions
How will the integration of Akadeum’s T Cell Leukopak Isolation Kit affect Charles River’s projected revenue and cash flow in the upcoming quarters?
What impact does this partnership have on Charles River’s competitive positioning in the cell therapy market compared to peers like CRISPR Therapeutics and Kite Pharma?
When are the key regulatory or commercial milestones expected for the Cell Therapy Flex Program that could influence the stock’s valuation?